FDA Vows Modernization to Keep Up With Biotech Advances
- History of medicine at great inflection point: Gottlieb
- FDA needs policies as scientifically advanced as drugs tested
This article is for subscribers only.
A week after its landmark approval of the first treatment that works by genetically altering a patient’s cells, the U.S. health regulator vowed to modernize to keep up with the fast-moving field of biotechnology research.
“We are at a point in the history of medicine that is similar to other great inflections in science where fundamental principles of science and medicine became firmly established as part of a leap in public health,” Food and Drug Administration Commissioner Scott Gottlieb said in a speech in Washington. “FDA’s goal is to make sure that our policies are as scientifically advanced as the products we’re being asked to evaluate.”